Evaluating Ebola Therapies — The Case for RCTs

Publisher Website
Google Scholar
Abstract
The worst Ebola epidemic in history is ongoing. With the number of deaths from Ebola virus disease (EVD) already in the thousands and predicted to rise to tens of thousands,1 the situation is tragic. No treatments have yet been shown to be safe and effective in patients with EVD. Some candidate therapies have shown benefit in animal models of infection, and others have shown activity against certain Ebola strains in cell culture, but concerns have been raised about possible toxicity of some of these agents. There is an urgent need to identify therapies that are effective and safe, and well-designed clinical trials are the fastest and most reliable way to achieve that goal.